Abstract
Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have